BioCryst Pharmaceuticals Inc. (BCRX)

3.35
0.04 1.18
NASDAQ : Health Technology
Prev Close 3.39
Open 3.39
Day Low/High 3.29 / 3.41
52 Wk Low/High 2.80 / 9.95
Volume 872.96K
Avg Volume 2.26M
Exchange NASDAQ
Shares Outstanding 110.31M
Market Cap 383.89M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Notable Two Hundred Day Moving Average Cross - BCRX

Notable Two Hundred Day Moving Average Cross - BCRX

In trading on Monday, shares of BioCryst Pharmaceuticals, Inc. crossed below their 200 day moving average of $7.66, changing hands as low as $7.58 per share.

BioCryst Pharmaceuticals is Now Oversold (BCRX)

BioCryst Pharmaceuticals is Now Oversold (BCRX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: Hess Is Undervalued

'Mad Money' Lightning Round: Hess Is Undervalued

Cramer would go with Salesforce.com but avoid BioCryst Pharmaceuticals.

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Caution, not aggression, will be the rule next week, Cramer says.

Interesting BCRX Put And Call Options For May 17th

Interesting BCRX Put And Call Options For May 17th

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the May 17th expiration.

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

BioCryst Announces Nature Publication Demonstrating Efficacy Of BCX4430 In A Non-Human Primate Model Of Filovirus Infection

BioCryst Announces Nature Publication Demonstrating Efficacy Of BCX4430 In A Non-Human Primate Model Of Filovirus Infection

Broad Spectrum Activity Shown Against Multiple RNA Virus Biothreats

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Perilous Reversal Stock: Biocryst Pharmaceuticals (BCRX)

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Interesting BCRX Put And Call Options For April 19th

Interesting BCRX Put And Call Options For April 19th

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the April 19th expiration.

First Week Of BCRX September 20th Options Trading

First Week Of BCRX September 20th Options Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading this week, for the September 20th expiration.

Biocryst Pharmaceuticals (BCRX) Is Today's Perilous Reversal Stock

Biocryst Pharmaceuticals (BCRX) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

BioCryst Receives Additional NIAID Funding To Advance Development Of BCX4430 To Treat Marburg Virus Disease

BioCryst Receives Additional NIAID Funding To Advance Development Of BCX4430 To Treat Marburg Virus Disease

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option to conduct the investigational new drug (IND) enabling...

BioCryst Files Peramivir NDA For The Treatment Of Influenza

BioCryst Files Peramivir NDA For The Treatment Of Influenza

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New ...

BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors For Hereditary Angioedema Into Preclinical Development

BioCryst Advances Second Generation Oral Plasma Kallikrein Inhibitors For Hereditary Angioedema Into Preclinical Development

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has selected two optimized plasma kallikrein inhibitors to advance into preclinical development as potential once-daily, oral treatments for the ...

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst To Present At Two Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the following investor...

BCRX January 2016 Options Begin Trading

BCRX January 2016 Options Begin Trading

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading today, for the January 2016 expiration.

January 2015 Options Now Available For BioCryst Pharmaceuticals (BCRX)

January 2015 Options Now Available For BioCryst Pharmaceuticals (BCRX)

Investors in BioCryst Pharmaceuticals, Inc. saw new options begin trading today, for the January 2015 expiration.

BioCryst Initiates OPuS-1: A Phase 2a Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema

BioCryst Initiates OPuS-1: A Phase 2a Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has dosed the first subject in OPuS-1 ( Oral Prophylaxi S-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in...

BioCryst Provides Corporate Update And Reports Third Quarter 2013 Financial Results

BioCryst Provides Corporate Update And Reports Third Quarter 2013 Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the third quarter ended September 30, 2013.

TheStreet Quant Rating: D- (Sell)